| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.9 |